NCT06637020View on ClinicalTrials.gov

Phase Ib Clinical Study of HDM1005 Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

December 27, 2024

Study Completion Date

February 14, 2025

Conditions
Overweight and Obesity
Interventions
DRUG

HDM1005 injection or placebo

Within each cohort, subjects are randomized in a 4:1 ratio to receive either HDM1005 injection or placebo subcutaneously.

Trial Locations (1)

230000

The Second Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

INDUSTRY

NCT06637020 - Phase Ib Clinical Study of HDM1005 Injection | Biotech Hunter | Biotech Hunter